Overview
Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). NASH is an advanced form of NAFLD where the liver inflammation occurs owing to fat deposition in liver. The fat accumulation may be induced by genetic abnormalities, metabolic dysfunction, drug induced damages, etc. Untreated and advanced NASH is one of the major reason for liver cirrhosis and sever liver damage such as liver failure. Presently three distinct method are used for diagnosis and monitoring of NASH, those are biopsy derived histopathology, imaging tools like transient elastography (TE), magnetic resonance imaging (MRI), etc., and in vitro diagnostic using biomarkers. As per the World Gastroenterology Organization It is estimated that around 20% to 30% of world population is affected with NAFLD.
Global Non-alcoholic Steatohepatitis Biomarker Market: Drivers and Trends
Increasing prevalence of NASH associated conditions like obesity and diabetes are expected to drive the growth of NASH biomarkers market. According to Deutsche Bank around 45 million people are anticipated to be affected by NASH in the U.S. and EU5 countries by 2025. Also there are many industry players investing on development of NASH therapeutic drugs, and most of them are in phase II or III of clinical trials. Their requirement of non-invasive diagnostic tools for monitoring their drug effectiveness is expected to drive the growth for NASH biomarkers market over the forecasted period. Biomarkers based NASH diagnostic tests are proposed to be at lower cost and non-invasive which is expected to make them a preferred tool for NASH diagnosis over invasive liver biopsy and costly imaging techniques. Ongoing research in discovery and development of novel NASH biomarkers is expected to drive the growth of NASH biomarkers market. However presently available NASH biomarkers are less accurate and have little efficacy which makes their usage limited. Also their results are overlapping with other metabolic disorders which is anticipated to restrain the growth of NASH biomarkers market.
Global Non-alcoholic Steatohepatitis Biomarker Market: Segmentation
Based on the marker type the global non-alcoholic steatohepatitis biomarkers market is segmented in to five segments viz. serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Serum biomarkers are expected to dominate the global NASH biomarkers market in the first half of the forecasted period. Owing to their indirect relation with NASH and other limitations they are expected to lose their market share in the second half of forecasted period. The Hepatic fibrosis markers are expected to grow exponentially over the forecasted period owing to their more accuracy and efficacy. This marker type segment is expected to hold the largest share of NASH biomarkers market by 2026. With expected launch of new diagnostic tools by Genfit SA and Exalenz Biosciences Ltd. the other markers segment is expected to have an exponential growth over the forecasted period.
Based on end-user, the global non-alcoholic steatohepatitis biomarkers market has been segmented into contract research organization (CRO) & pharmaceutical industry, academic research institutes, hospitals, and diagnostic laboratories. Owing to the requirement of non-invasive diagnostic tools for routine monitoring of drug therapy effectiveness during the clinical trial of drug candidates, the CRO & pharmaceutical industry end-user segment is expected to have a moderate growth over the forecasted period. However towards the end of forecasted period this segment is expected to be superseded by hospital and diagnostic laboratories end-user segment. With expected launch of companion diagnostic tests along with NASH therapeutic drugs the hospitals and diagnostic laboratories segments of end-user are expected to witness an exponential growth over forecasted period. The hospital end-user segment is expected to grow at CAGR of 36.6% while diagnostic laboratories segment is expected to grow at CAGR of 37.0% over the forecasted period.
Regional Outlook
Geographically, the non-alcoholic steatohepatitis biomarkers market has been segmented into five regions: North America, Latin America, Europe, Asia Pacific and Middle East and Africa. These regions have been further segmented by marker type and end-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global non-alcoholic steatohepatitis biomarkers market.
Key Players Mentioned in this Report are:
The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include One Way Liver S.L., BioPredictive S.A.S, Siemens Heathcare Pvt. Ltd. (now Siemens Healthineers), Genfit SA, Exalenz Biosciences Ltd., Quest Diagnostic Incorporated, Prometheus Laboratories Corp. (part of Nestle Health Sciences) and SNIBE diagnostics.
The global non-alcoholic steatohepatitis biomarkers market has been segmented as follows:
by Marker Type
by End-User
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Marker Type Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.4.4. Trends
4.5. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast, 2016 – 2024
4.5.1. Pricing – Actuals and Projections, 2016-2024 (US$)
4.5.2. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Value Chain Analysis
4.8. Market Outlook
Chapter 5. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Marker Type
5.1. Introduction & Definition
5.2. Key Trends
5.3. Comparison Matrix
5.4. Market Size (US$ Mn) Forecast By Marker Type
5.4.1. Serum Biomarkers
5.4.2. Hepatic Fibrosis Markers
5.4.3. Oxidative Stress Markers
5.4.4. Apoptosis Markers
5.4.5. Others (miRNA, carbon isotopes)
5.5. Market Attractiveness By Marker Type
Chapter 6. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By End User
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Comparison Matrix
6.5. Market Size (US$ Mn) Forecast By End User
6.5.1. Contract Research Organizations / pharmaceutical industry
6.5.2. Academic Research Institute
6.5.3. Hospitals
6.5.4. Diagnostic Laboratories
6.6. Market Attractiveness By End User
Chapter 7. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Key Trends
7.3. Market Size (US$ Mn) Forecast By Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness By Region
Chapter 8. North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Marker Type
8.4.1. Serum Biomarkers
8.4.2. Hepatic Fibrosis Markers
8.4.3. Oxidative Stress Markers
8.4.4. Apoptosis Markers
8.4.5. Others (miRNA, carbon isotopes)
8.5. Market Size (US$ Mn) Forecast By End User
8.5.1. Contract Research Organizations / pharmaceutical industry
8.5.2. Academic Research Institute
8.5.3. Hospitals
8.5.4. Diagnostic Laboratories
8.6. Market Size (US$ Mn) Forecast, By Country
8.6.1. U.S.
8.6.2. Canada
8.7. Market Attractiveness Analysis
8.7.1. By Marker Type
8.7.2. By End User
8.7.3. By Country
Chapter 9. Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Marker Type
9.4.1. Serum Biomarkers
9.4.2. Hepatic Fibrosis Markers
9.4.3. Oxidative Stress Markers
9.4.4. Apoptosis Markers
9.4.5. Others (miRNA, carbon isotopes)
9.5. Market Size (US$ Mn) Forecast By End User
9.5.1. Contract Research Organizations / pharmaceutical industry
9.5.2. Academic Research Institute
9.5.3. Hospitals
9.5.4. Diagnostic Laboratories
9.6. Market Size (US$ Mn) Forecast, By Country
9.6.1. U.K.
9.6.2. France
9.6.3. Germany
9.6.4. Spain
9.6.5. Rest of Europe
9.7. Market Attractiveness Analysis
9.7.1. By Marker Type
9.7.2. By End User
9.7.3. By Country
Chapter 10. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings / Developments
10.3. Key Trends
10.4. Market Size (US$ Mn) Forecast By Marker Type
10.4.1. Serum Biomarkers
10.4.2. Hepatic Fibrosis Markers
10.4.3. Oxidative Stress Markers
10.4.4. Apoptosis Markers
10.4.5. Others (miRNA, carbon isotopes)
10.5. Market Size (US$ Mn) Forecast By End User
10.5.1. Contract Research Organizations / pharmaceutical industry
10.5.2. Academic Research Institute
10.5.3. Hospitals
10.5.4. Diagnostic Laboratories
10.6. Market Size (US$ Mn) Forecast, By Country
10.6.1. Japan
10.6.2. China
10.6.3. India
10.6.4. Rest of APAC
10.7. Market Attractiveness Analysis
10.7.1. By Marker Type
10.7.2. By End User
10.7.3. By Country
Chapter 11. Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings / Developments
11.3. Key Trends
11.4. Market Size (US$ Mn) Forecast By Marker Type
11.4.1. Serum Biomarkers
11.4.2. Hepatic Fibrosis Markers
11.4.3. Oxidative Stress Markers
11.4.4. Apoptosis Markers
11.4.5. Others (miRNA, carbon isotopes)
11.5. Market Size (US$ Mn) Forecast By End User
11.5.1. Contract Research Organizations / pharmaceutical industry
11.5.2. Academic Research Institute
11.5.3. Hospitals
11.5.4. Diagnostic Laboratories
11.6. Market Size (US$ Mn) Forecast, By Country
11.6.1. Brazil
11.6.2. Mexico
11.6.3. Argentina
11.6.4. Rest of Latin America
11.7. Market Attractiveness Analysis
11.7.1. By Marker Type
11.7.2. By End User
11.7.3. By Country
Chapter 12. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings / Developments
12.3. Key Trends
12.4. Market Size (US$ Mn) Forecast By Marker Type
12.4.1. Serum Biomarkers
12.4.2. Hepatic Fibrosis Markers
12.4.3. Oxidative Stress Markers
12.4.4. Apoptosis Markers
12.4.5. Others (miRNA, carbon isotopes)
12.5. Market Size (US$ Mn) Forecast By End User
12.5.1. Contract Research Organizations / pharmaceutical industry
12.5.2. Academic Research Institute
12.5.3. Hospitals
12.5.4. Diagnostic Laboratories
12.6. Market Size (US$ Mn) Forecast, By Country
12.6.1. South Africa
12.6.2. GCC Countries
12.6.3. Rest of MEA
12.7. Market Attractiveness Analysis
12.7.1. By Marker Type
12.7.2. By End User
12.7.3. By Country
Chapter 13. Competition Landscape
13.1. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market – Competition Matrix (By Tier and Size of companies) (2015)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.2.1. BioPredictive S.A.S
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Product Portfolio
13.2.1.3. SWOT Analysis
13.2.1.4. Strategic Overview
13.2.2. One Way Liver S.L.
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Product Portfolio
13.2.2.3. SWOT Analysis
13.2.2.4. Strategic Overview
13.2.3. Genfit SA
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Quest Diagnostics Incorporated
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Financial Overview
13.2.4.5. Strategic Overview
13.2.5. Prometheus Laboratories Inc. (Part of Nestle Health Sciences)
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Product Portfolio
13.2.5.3. SWOT Analysis
13.2.5.4. Financial Overview
13.2.5.5. Strategic Overview
13.2.6. Siemens Healthcare Private Ltd. (now Siemens Healthineers)
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Product Portfolio
13.2.7.3. SWOT Analysis
13.2.7.4. Financial Overview
13.2.7.5. Strategic Overview
13.2.8. Exalenz Biosciences Ltd.
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Product Portfolio
13.2.8.3. SWOT Analysis
13.2.8.4. Financial Overview
13.2.8.5. Strategic Overview
Chapter 14. Key Take Away
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers